
<DOC>
<DOCNO>WT03-B24-156</DOCNO>
<DOCOLDNO>IA064-000377-B048-330</DOCOLDNO>
<DOCHDR>
http://www.sosei.com:80/Companies/sosei.html 206.86.52.80 19970112094659 text/html 11768
HTTP/1.0 200 OK
Date: Sun, 12 Jan 1997 09:47:03 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 11585
Last-modified: Sun, 12 May 1996 19:30:19 GMT
</DOCHDR>
<HTML><HEAD><TITLE>Sosei Home Page</TITLE></HEAD>
<BODY BGCOLOR=#FFFFFF><H1><IMG  Align=top SRC="../Graphics/sosei.gif">Sosei Co., Ltd.</H1><H3>Corporate Profile</H3>
<HR>
7F, MS Bldg., 3-4-9 Misaki-cho, Chiyoda-ku<BR>
Tokyo, Japan 101<BR>
Telephone: 81-3-5210-3290<BR>
Fax: 81-3-5210-3291<P>

<B>History:</B><BR>
<TABLE BORDER=1>
<td><B>1990</B></td><td align = right><EM>June</EM></td><td><IMG SRC="../Graphics/sosei_bullet.gif">&#32;S. Tamura and T. Nakamura incorporated Sosei</td><tr>

<td><B>1991</B></td><td align = right><EM>April</EM></td><td><IMG SRC="../Graphic
s/sosei_bullet.gif">&#32;S. Tamura became full time President and CEO</td><tr>

<td rowspan =3><B>1992</B></td><td align = right valign=top><EM>May</EM></td><td><IMG SRC="../Graphic
s/sosei_bullet.gif">&#32;Agreement with Sumitomo on HGF signed<BR>
<IMG SRC="../Graphic
s/sosei_bullet.gif">&#32;Recieved first payment</td><tr>

<td align = right><EM>September</EM></td><td><IMG SRC="../Graphic
s/sosei_bullet.gif">&#32;S.R. One invested $875K</td><tr>

<td align = right><EM>December</EM></td><td><IMG SRC="../Graphic
s/sosei_bullet.gif">&#32;New office opened in Tokyo</td><tr>

<td rowspan =2><B>1993</B></td><td align = right><EM>January</EM></td><td><IMG SRC="../Graphic
s/sosei_bullet.gif">&#32;M. Kimura, Director of Planning and Marketing, hired</td><tr>

<td align = right><EM>May</EM></td><td><IMG SRC="../Graphic
s/sosei_bullet.gif">&#32;Reported first profit (fiscal year; June-May)</td><tr>

<td rowspan=3 ><B>1994</B></td><td align = right valign=top><EM>January</EM></td><td><IMG SRC="../Graphic
s/sosei_bullet.gif">&#32;Schroder Ventures, S.R. One, Oxford Bioscience and Biotechnology Investment (Rothschild Asset Management) committed to invest $4M</td><tr>

<td align = right><EM>July</EM></td><td><IMG SRC="../Graphic
s/sosei_bullet.gif">&#32;Nisshin Oil committed to fund IP3/IP4 project</td><tr>

<td align = right><EM>December</EM></td><td><IMG SRC="../Graphic
s/sosei_bullet.gif">&#32;T. Kiley and T. Watanabe joined the Board<tr valign=middle>

<td valign=middle rowspan=4><B>1995</B><td align = right valign=top><EM>March</EM><td><IMG SRC="../Graphic
s/sosei_bullet.gif">&#32;Sosei License Option Fund being raised ($4M committed as of April 31)<tr>

<td align = right><EM>June</EM><P></td><td><IMG SRC="../Graphic
s/sosei_bullet.gif">&#32;Baruch Blumberg (Nobel Laureate, discovered of HBV) became a Board Member and Scientific Advisor</td><tr>

<td align = right><EM>July</EM></td><td><IMG SRC="../Graphic
s/sosei_bullet.gif">&#32;E. Yamada, Senior Director of Scientific Affairs, hired</td> 
<tr>
<td align = right valign= top><EM>September</EM></td><td><IMG SRC="../Graphic
s/sosei_bullet.gif">&#32;T. Watanabe nominated to Representative Director and Chairman of Investment Committee, License Fund.</td>
<tr>
<td><B>1996</B>
<td align=right><EM>February</EM></td><td><IMG SRC="../Graphics/sosei_bullet.gif">&#32;Joined ERATO Project (Mikoshiba Calciosigmal Net)</td>
</TABLE><P>

<B>Founders: </B>Shinichi Tamura and Tetsuo Nakamura<P>

<B>Incorporation: </B>June 22, 1990<P>

<B>Corporate Overview:</B><BR>
<BLOCKQUOTE><I>Business:</I><BR>
Seed Money Investment and License of Intellectual Property Rights. To become the most reliable "cultural interpreter" between innovative biotech firms in the U.S./Europe and conservative but reliable medical and pharmaceutical companies and research labs in Japan by:<P>
1. Accessing novel biopharmaceutical science in Japan by
expediting the licensing and commercialization of university
discovered technologies.<P>

2. Developing strategic licensing arrangements with such science both inside and outside Japan.<P>
3. Providing the most reliable platform in Japan for small biotech firms in the U.S. and Europe looking for Japanese corporate partners to establish most efficient global R&amp;D strategy.</BLOCKQUOTE><P>

<B>Track Record / May, 1995</B><BR>
<BLOCKQUOTE>Only major deals, for which Sosei played a pivotal role, with size close to or in excess of two billion yen are listed.</BLOCKQUOTE>

<TABLE border = 4>
<th>Date</th><th>Licenser</th><th>Area</th><th>Licensee</th><th>License Fee</th><tr>

<td ALIGN=CENTER VALIGN=MIDDLE>May<BR>1995</td><td ALIGN=CENTER VALIGN=MIDDLE>Geron</td><td>Anticancer</td><td>Kyowa Hakko</td><td>$30M(+royalty)<tr>

<td ALIGN=CENTER VALIGN=MIDDLE>April<BR>1994</td><td ALIGN=CENTER VALIGN=MIDDLE>Pharmacyclics</t><td>MRI contrast medium</td><td> n.a.</td><td>n.a.</td><tr>
                                       
<td ALIGN=CENTER VALIGN=MIDDLE>March<BR>1994</td><td ALIGN=CENTER VALIGN=MIDDLE>Agene</td><td>Aging Project</td>
<td> Ministry of Welfare<BR>
 Nippon Roche<BR>
 Meiji Seika<BR>
 Eisai<BR>
 Kissei Pharmaceutical<BR>
</td><td>3 billion yen (equity)</td><tr>

<td ALIGN=CENTER VALIGN=MIDDLE>June<BR>1993</td><td ALIGN=CENTER VALIGN=MIDDLE>GenPharm</td><td>Human antibody</td><td>Eisai</td><td>2.5 billion yen (+royalty)</td><tr>

<td ALIGN=CENTER VALIGN=MIDDLE>May<BR>1992</td><td ALIGN=CENTER VALIGN=MIDDLE>Sosei </td><td>HGF</td><td>Sumitomo  Pharmaceutical</td><td>n.a.</td><tr>

<td ALIGN=CENTER VALIGN=MIDDLE>1989-1990</td><td ALIGN=CENTER VALIGN=MIDDLE>IDEC</td><td>Idiotype antibody</td><td> Institute of Immunology Zenyaku</td>
 <td>2.3 billion yen (+royalty)</td></TABLE><BR>

<B>Why Sosei is Successful:</B>
<BLOCKQUOTE>1. Sosei has invented an efficient system to identify and obtain important biopharmaceutical technology arising in top-tier Japanese universities.<P>

2. Sosei has already identified and obtained key technology in a variety of medically important areas (e.g. liver disease).<P>

3. Sosei has already established a track record of strategic alliances both for itself (e.g. Sumitomo-unannounced significant deal) and for third parties (e.g. Geron - $30M)<P>

4. Sosei's management, business advisors and shareholders represent top quality  experience in global licensing and investment activities.<P>

5. Sosei has outstanding scientific advisors especially in hepatology and gerontology related research.<P>

6. Sosei's international set-up has given it unique acess to U.S.,
Europe and Japan for funding, markets, technology and patenting and
regulatory flexibility.<P>

7. Relationships are accelerating Sosei's rapid progress:<P>

<UL><LI> Sumitomo Pharmaceutical Co., Ltd. has made a serious commitment for HGF development, ensuring significant license fees and royalties paid to Sosei.
<LI> Sosei has helped Koseisho (Japanese FDA/NIH) set up consortium (Agene) providing research funds for the aging project as well as strong ties to the member companies ($30M fund).
<LI> Tokyo University and Osaka University give access to innovative technologies in Japan.
</UL>

8. Global venture capital funding already established:<P>

<UL><LI> $0.9M investment from S.R. One in Sept. '92.
<LI> $4M investment commitment from Schroder, S.R. One, Oxford Bioscience and Biotechnology Investments Limited (Advised by Rothschilds) in January, 1994.
<LI>$4M raised for the <A HREF = "../licensefund.html">License Fund</A> in mid 1995.
</UL></BLOCKQUOTE>

<B>Latest Corporate Partners (Example):</B>
<UL><LI> Sumitomo Pharmaceuticals
<LI> Snow Brand
<LI> Kissei
<LI> Takara Shuzo
<LI> Nisshin Oil
<LI> Fujirebio
<LI> Institute of Immunology
<LI> Genentech
<LI> GenPharm
<LI> Geron
<LI> ONYX
<LI> <A HREF = "http://www.generics.co.uk">Generics Group</A>
<LI> ERATO (Exploratory Research for Advanced Technology): JRDC - Ministry of Science and Technology
<LI> Tokyo University
<LI> Osaka University
<LI> Hokkaido University
<LI> Ochanomizu University
<LI> Hiroshima Universiy
<LI> Mitsubishi Chemical
</UL>

<B>Management:</B><P>
Shinichi Tamura - President and CEO, Board Director, Co-founder<BR>
<a href="mailto:stamura@sosei.com">stamura@sosei.com </a> 
<P>
Tetsuo Watanabe - Representative Director, Chairman of Investment Committee<P>

Ei Yamada - Senior Director, Scientific Affairs<BR>
<a href="mailto:eyamada@sosei.com">eyamada@sosei.com</a><P>

Masaya Kimura - Director, Planning & Marketing<BR>
<a href="mailto:maya@sosei.com">maya@sosei.com</a><P>

<B>Board of Directors:</B><P>
<a href="mailto:stamura@sosei.com">Shinichi Tamura</a><BR>
Representative Director, President and CEO<BR>
Ex-representative Director (CEO), Genentech Ltd.(Genentech, Japan)<P>

Nobuo Matsuki<BR>
Chairman<BR>
General Partner, Schroder PTV Partners K.K.<BR>
<A HREF="mailto:nmatsuki@magical.egg.or.jp">nmatsuki@magical.egg.or.jp</A><P>

James E. Foley<BR>
Vice President, SmithKline Beecham International<BR>
<A HREF="mailto:James.FOLEY@nca.sb.com">James.FOLEY@nca.sb.com</A><P>

Baruch S. Blumberg<BR>
Nobel Prize Laureate<BR>
Master of Balliol College at Oxford University<BR>
<a href="mailto:BS_Blumberg@fccc.edu">BS_Blumberg@fccc.edu</a><P>

Jeremy Curnock Cook<BR>
Director, Rothschild Asset Management Ltd., Advisors to BIL<P>

Tom Kiley<BR>
Former VP of Corporate Development and General Counsel for Genentech<BR>
<A HREF="mailto:tomkiley@aol.com">tomkiley@aol.com</A><P>

Jonathan J. MacQuitty</a><BR>
President and CEO of GenPharm International<BR>
<a href="mailto:lhunter353@aol.com">lhunter353@aol.com</A><P>

Shoko Matsui<BR>
Partner, Schroder PTV Partners K.K.<BR>
<a href="mailto:smatsui@magical.egg.or.jp">smatsui@magical.egg.or.jp</a><P>

Edmund M. Olivier<BR>
General Partner, Oxford Bioscience Partners<BR>
<a href="mailto:olivier@realm.net">olivier@realm.net</a><P>

Tetsuo Watanabe<BR>
Representative Director, Chairman of Investment Committee, License Fund<BR>
Senior Advisor of Asahi Chemical Industry Co., Ltd.<P>

<B>Business Advisors:</B><P>

Hans Vauthier<BR>
Former Director of marketing and member of the Pharma Management Committee CIBA-GEIGY AG<P>

Tetsuo Nakamura<BR>
President and CEO of Institute of Immunology<P>

Clifford Orent<BR>
Chairman, President & Chief Executive Officer of Terrapin Technologies, Inc.<BR>
<a href="mailto:orent@trpntech.com">orent@trpntech.com</a><P>

<B>Scientific Advisors:</B><P>

Baruch S. Blumberg, M.D., Ph.D.<BR>
Nobel Prize Laureate<BR>
Master of Balliol College at Oxford University<BR>
<a href="mailto:BS_Blumberg@fccc.edu">BS_Blumberg@fccc.edu</a><P>

Toshifumi Kagiya, M.D., Ph.D.<BR>
Director, Osaka Health Office of All Nippon Airways<BR>
Assistant Professor at Osaka University<BR>
Focused on Cardiovascular Research<P>

Katsuhiko Mikoshiba, M.D.<BR>
Professor at Tokyo University<BR>
Focused on Signal Transduction, Neuroscience<P>

Richard Miller, M.D.<BR>
President and CEO at Pharmacyclics<BR>
Co-founder of IDEC and CellPro<BR>
Assistant Professor at Stanford University<BR>
Focused on Oncology<BR>
<A HREF="mailto:Richard@Pclx.com">Richard@Pclx.com</A><P>

Toshikazu Nakamura, Ph.D.<BR>
Professor at Osaka University<BR>
Discoverer of HGF<BR>
Focused on Cell Biology, Hepatology<P>

<A HREF = "http://www.sosei.com/"><IMG  Align=Middle SRC="../Graphics/home_button.gif"></A><A HREF = "http://www.sosei.com/">  Home Page</A><P>
<HR></BODY>
<ADDRESS><FONT SIZE=3>
Updated; February 7, 1996.
Copyright &copy; 1996 <A HREF = "http://www.genweb.com/">GenWeb</A>.
All rights reserved.</FONT></ADDRESS>

<!--  INFORMATION ABOUT THE CONTACT PERSON FILLING OUT THIS FORM
Date:April 5, 1995
Name: Shinichi Tamura
Title: President and CEO
Company Name: Sosei Co., Ltd.
Adress: 7F, MS Bldg., 3-4-9 Misaki-cho, Chiyoda-ku
City: Tokyo
State: Tokyo
Zip Code: 101
Telephone Number: 81-3-5210-3290
Fax Number: 81-3-5210-3291
e-mail: 1.tamura@sosei.com 2. mail08110@pop.net> -->

<!-- revised: Sunday, June 4, 1995; 5:00 PM >

<!-- revised: Wednesday,  July 12, 1995 -->
<!-- revised: Saturday, 09/23/95 CC -->
</HTML>
</DOC>